Trial
NCT03823131
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Chase Heaton, MD
Collaborators
Incyte Corporation; OncoSec Medical Incorporated
Condition
Metastatic Head and Neck Squamous Cell Carcinoma
Intervention
ImmunoPulse
Why stopped
Treatment Ineffective
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-05-09